Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Disorders of Sex Development-Novel Regulators, Impacts on Fertility, and Options for Fertility Preservation

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Blood Metabolite Signatures of Metabolic Syndrome in Two Cross-Cultural Older Adult Cohorts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Neonatal HDL counteracts placental vascular inflammation via S1P-S1PR1 axis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Fluorescent Analogues of Human α-Calcitonin Gene-Related Peptide with Potent Vasodilator Activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Atopic dermatitis is associated with increased use of social benefits: a register-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Analgesics use and withdrawal in people with dementia - a register-based Danish study and a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Psoriasis is a chronic immune-mediated inflammatory disease affecting women of childbearing potential. Biologic agents, notably Tumor Necrosis Factor inhibitors (TNFi), are the only current non-contraindicated systemic treatment option during pregnancy. TNFi comprised of complete immunoglobulin G (IgG) antibodies antibodies (adalimumab, golimumab, and infliximab) actively cross the placenta from the second trimester and are detectable in the child up to one year postpartum. Data on safety of TNFi are conflicting; however a trend towards drug-specific harm has been reported, with increased risk of congenital malformations and preterm birth. TNFi exposure may alter the immune system of the infant towards hypersensitivity and reduced response to intracellular infections. Confounding by indication should be considered, as chronic inflammatory disease itself may pose a risk of adverse pregnancy outcomes. The quality of the current evidence is very low and no studies specifically address TNFi safety in women with psoriasis. Nonetheless, risks associated with TNFi treatment must be balanced against the as-yet uncertain risk of adverse outcomes in infants born to women with severe psoriasis. We searched PubMed using Medical Subject Headings (MeSH) terms and identified relevant studies and guidelines. Herein, we present the current knowledge of the use and safety of TNFi during pregnancy in women with psoriasis.

OriginalsprogEngelsk
TidsskriftInternational Journal of Molecular Sciences
Vol/bind19
Udgave nummer5
ISSN1661-6596
DOI
StatusUdgivet - 3 maj 2018

ID: 55741536